Literature DB >> 30251118

Leptin-induced cardiomyocyte hypertrophy is associated with enhanced mitochondrial fission.

Chian Ju Jong1,2, Justin Yeung1, Emily Tseung1, Morris Karmazyn3.   

Abstract

Cardiac pathology including hypertrophy has been associated with an imbalance between mitochondrial fission and fusion. Generally, well-balanced mitochondrial fission and fusion are essential for proper functions of mitochondria. Leptin is a 16-kDa appetite-suppressing protein which has been shown to induce cardiomyocyte hypertrophy. In the present study, we determined whether leptin can influence mitochondrial fission or fusion and whether this can be related to its hypertrophic effect. Cardiomyocytes treated for 24 h with 3.1 nM leptin (50 ng/ml), a concentration representing plasma levels in obese individuals, demonstrated an increase in surface area and a significant 1.6-fold increase in the expression of the β-myosin heavy chain. Mitochondrial staining with MitoTracker Green dye showed elongated structures in control cells with an average length of 4.5 µm. Leptin produced a time-dependent increase in mitochondrial fragmentation with decreasing mitochondrial length. The hypertrophic response to leptin was also associated with increased protein levels of the mitochondrial fission protein dynamin-related protein1 (Drp1) although gene expression of Drp1 was unaffected possibly suggesting post-translational modifications of Drp1. Indeed, leptin treatment was associated with decreased levels of phosphorylated Drp1 and increased translocation of Drp1 to the mitochondria thereby demonstrating a pro-fission effect of leptin. As calcineurin may dephosphorylate Drp1, we determined the effect of a calcineurin inhibitor, FK506, which prevented leptin-induced hypertrophy as well as mitochondrial fission and mitochondrial dysfunction. In conclusion, our data show that leptin-induced cardiomyocyte hypertrophy is associated with enhanced mitochondrial fission via a calcineurin-mediated pathway. The ability of leptin to stimulate mitochondrial fission may be important in understanding the role of this protein in cardiac pathology especially that related to mitochondrial dysfunction.

Entities:  

Keywords:  Calcineurin; Hypertrophy; Leptin; Mitochondria

Mesh:

Substances:

Year:  2018        PMID: 30251118     DOI: 10.1007/s11010-018-3450-5

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  5 in total

1.  Chronic exposure to ozone induces cardiac antioxidant response and overexpression of either mitochondrial fision protein DRP1 and hipertrophyc-related proteins.

Authors:  Nancy P Gómez-Crisóstomo; Selva Rivas-Arancibia; Erika Rodríguez-Martínez; Erick N De la Cruz-Hernández; Corazón de María Márquez Álvarez; Pablo Alexis Estrada Caraveo; Noemí Gelista Herrera; Marlen Valdés-Fuentes; Eduardo Martínez-Abundis
Journal:  J Bioenerg Biomembr       Date:  2022-03-26       Impact factor: 3.853

Review 2.  Novel Insights and Current Evidence for Mechanisms of Atherosclerosis: Mitochondrial Dynamics as a Potential Therapeutic Target.

Authors:  Dan Li; Shengjie Yang; Yanwei Xing; Limin Pan; Ran Zhao; Yixi Zhao; Longtao Liu; Min Wu
Journal:  Front Cell Dev Biol       Date:  2021-07-07

Review 3.  Regulation of Mitochondrial Quality Control by Natural Drugs in the Treatment of Cardiovascular Diseases: Potential and Advantages.

Authors:  Xing Chang; Wenjin Zhang; Zhenyu Zhao; Chunxia Ma; Tian Zhang; Qingyan Meng; Peizheng Yan; Lei Zhang; Yuping Zhao
Journal:  Front Cell Dev Biol       Date:  2020-12-23

4.  STVNa Attenuates Isoproterenol-Induced Cardiac Hypertrophy Response through the HDAC4 and Prdx2/ROS/Trx1 Pathways.

Authors:  Fei Liu; Hao Su; Bo Liu; Ying Mei; Qingjin Ke; Xiaoou Sun; Wen Tan
Journal:  Int J Mol Sci       Date:  2020-01-20       Impact factor: 5.923

5.  NFATc3-dependent expression of miR-153-3p promotes mitochondrial fragmentation in cardiac hypertrophy by impairing mitofusin-1 expression.

Authors:  Tao Wang; Mei Zhai; Sheng Xu; Murugavel Ponnusamy; Yan Huang; Cui-Yun Liu; Man Wang; Chan Shan; Pei-Pei Shan; Xiang-Qian Gao; Kai Wang; Xin-Zhe Chen; Jing Liu; Jing-Yi Xie; De-Yu Zhang; Lu-Yu Zhou; Kun Wang
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.